<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liver lesion evaluation in patients at risk for hepatocellular carcinoma using Liver Imaging Reporting and Data System (LI-RADS) categorization&lt;SUP&gt;[1]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liver lesion evaluation in patients at risk for hepatocellular carcinoma using Liver Imaging Reporting and Data System (LI-RADS) categorization<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Liver lesion evaluation in patients at risk for hepatocellular carcinoma using Liver Imaging Reporting and Data System (LI-RADS) categorization<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="2" width="25%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"> <p><strong>Select</strong> the target population:</p> Patients who have a liver lesion on imaging (eg, ultrasound) and who are at risk for HCC due to at least one of the following: <ul class="decimal_heading"> <li>Cirrhosis, with certain exceptions* </li> <li>Chronic hepatitis B virus infection </li> <li>Concurrent or prior diagnosis of HCC </li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"><strong>Perform</strong> one of the following studies, tailored for liver lesion evaluation:<sup>¶</sup> <ul class="decimal_heading"> <li>Contrast-enhanced CT </li> <li>Contrast-enhanced MRI </li> <li>Contrast-enhanced ultrasound (CEUS)‡</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"><strong>Categorize</strong> lesion(s) using LI-RADS </td> </tr> <tr class="divider_top"> <td class="subtitle1" colspan="4">LI-RADS categorization of liver lesions in patients at risk for hepatocellular carcinoma</td> </tr> <tr> <td class="subtitle2">Category</td> <td class="subtitle2">Assessment</td> <td class="subtitle2">Diagnostic considerations</td> <td class="subtitle2">Action</td> </tr> <tr class="divider_bottom"> <td class="centered">LR-1</td> <td>Definitely benign</td> <td>Includes hemangiomas with characteristic features or cysts.</td> <td> <ul> <li>Continue routine surveillance imaging for HCC<sup> Δ</sup> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">LR-2</td> <td>Probably benign</td> <td>Includes hemangioma without characteristic features and wedge-shaped arterioportal shunts.</td> <td> <ul> <li>For most patients, continue routine surveillance imaging for HCC<sup>Δ</sup> </li> <li>For some patients, image with a different modality or MRI contrast agent<sup>◊</sup> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">LR-3</td> <td>Intermediate probability of malignancy</td> <td>Includes dysplastic nodules, benign lesions without characteristic features, and rounded arterioportal shunts.</td> <td> <ul> <li>Repeat contrast-enhanced CT, MRI, or ultrasound for liver lesion evaluation in 3 to 6 months<sup>¶</sup> </li> <li>Continue serial imaging every 3 to 6 months while the lesion remains LR-3 for ≥2 years or until the lesion has a conclusive diagnosis<sup>§</sup> </li> <li>If the lesion remains LR-3 for ≥2 years on imaging follow-up, return to routine surveillance imaging for HCC<sup>Δ</sup> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">LR-4</td> <td>Probably HCC</td> <td>Includes HCC with some characteristic features.<sup>¥</sup></td> <td> <ul> <li>Multidisciplinary consultation to tailor further management. Options include: <ul> <li>Alternative or follow-up imaging </li> <li>Biopsy the lesion </li> <li>Presumptive treatment without conclusive diagnosis </li> </ul> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">LR-5</td> <td>Definitely HCC<sup>†</sup></td> <td>HCC with characteristic features.**</td> <td> <ul> <li>Treatment for HCC </li> <li>No biopsy needed </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">LR-M</td> <td>Probably or definitely malignant, not specific for HCC</td> <td> <p>Most LR-M lesions are malignant.</p> Includes HCC without characteristic features<sup>¶¶</sup> and other malignancies (eg, cholangiocarcinoma, combined hepatocellular carcinoma and cholangiocarcinoma, lymphoma, or metastasis). </td> <td> <ul> <li>Multidisciplinary consultation to tailor further management. Options include: <ul> <li>Evaluate for underlying malignancy<sup>ΔΔ</sup> </li> <li>Perform biopsy if it will alter management<sup>◊◊</sup> </li> </ul> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">LR-NC</td> <td>Not categorizable</td> <td> <p>Images are insufficient for assessment.</p> Common reasons include imaging protocol not tailored for liver lesion or images degraded from patient motion. </td> <td> <ul> <li>Repeat imaging for liver lesion evaluation with same or alternate modality in ≤3 months </li> </ul> </td> </tr> <tr> <td class="centered">LR-TIV</td> <td>Tumor in vein</td> <td>Unequivocal enhancing soft tissue in vein indicating tumor, either from HCC or another malignancy.</td> <td> <ul> <li>Multidisciplinary consultation to tailor further management. Options include:  <ul> <li>Alternative or follow-up imaging </li> <li>Biopsy the tumor in vein </li> <li>Presumptive treatment without histologic confirmation </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Evaluation of liver lesions in patients not at high risk for HCC is described elsewhere in UpToDate and is not addressed in this table. If there are multiple lesions, this table can be applied to each lesion. However, management choice is driven by the lesion that is the most suspicious (eg, growing, largest, and not definitely benign).</div><div class="graphic_footnotes">LI-RADS: Liver Imaging Reporting and Data System; HCC: hepatocellular carcinoma; CT: computed tomography; MRI: magnetic resonance imaging; OPTN: Organ Procurement and Transplantation Network.<br/>* LI-RADS assessment should not be applied to patients &lt;18 years old or those with cirrhosis from congenital hepatic fibrosis or secondary to vascular disorders (eg, Budd-Chiari syndrome, chronic portal vein occlusion, cardiac congestion, hereditary hemorrhagic telangiectasia).<br/>¶ Imaging technology and performance should adhere to standards required for liver lesion characterization, which are more stringent than those for routine abdominal imaging. Contrast-enhanced CT or MRI is preferred over ultrasound (CEUS) to characterize lesions where index of suspicion for HCC or malignancy is high or in patients with multiple lesions requiring LI-RADs categorization. Should the lesion prove to be LR-4, LR-5, or LR-M, CEUS cannot evaluate the entire liver to assess tumor burden for treatment planning nor diagnose HCC using the OPTN criteria for transplant evaluation. In addition, for technical reasons, CEUS cannot categorize multiple lesions simultaneously.<br/>Δ Surveillance imaging for adults at risk for HCC, usually performed with abdominal ultrasound without contrast, is described elsewhere in UpToDate.<br/><font class="lozenge">◊</font> Choice of additional imaging should be made in consultation with the radiologist.<br/>§ While the two-year follow-up represents our practice, stability over that time does not confirm that a lesion is benign.<br/>¥ On contrast-enhanced CT or MRI, in order to be categorized as LR-4, lesions that measure &lt;1 cm should be arterially enhancing and demonstrate at least one of these three features: nonperipheral washout, enhancing capsule, or growth. Lesions that are not arterially enhancing can also be categorized as LR-4 if they measure &gt;2 cm and demonstrate one of the three features or measure &lt;2 cm and demonstrate two of the three features. On CEUS, in order to be categorized as LR-4, lesions should be arterially enhancing without washout and measure &gt;1 cm, arterially enhancing with late and mild washout and measure &lt;1 cm, or not arterially enhancing with late and mild washout and measure &gt;2 cm.<br/>‡ If the lesion was diagnosed on CEUS, contrast-enhanced CT or MRI tailored for liver lesion evaluation should be performed to plan therapy.<br/>† For patients who are candidates for liver transplant, most LR-5 lesions meet OPTN criteria for diagnosis of HCC. Refer to UpToDate content for description of pertinent exceptions.<br/>** On contrast-enhanced CT or MRI, in order to be categorized as LR-5, lesions must be arterially enhancing and measure &gt;1 cm. Additionally, those measuring &gt;2 cm should demonstrate at least one of the following three features, and those measuring &gt;1 but &lt;2 cm should demonstrate at least two of the three features: non-peripheral washout, enhancing capsule, or growth. On CEUS, in order to be categorized as LR-5, lesions should measure &gt;1 cm and demonstrate arterial enhancement with late and mild washout. Growth is defined as ≥50% increase in size in ≤6 months with a threshold of ≥5 mm change to avoid error from measurement variability.<br/>¶¶ Examples of HCC without characteristic features are those without arterial enhancement or those with both arterial and delayed enhancement suggesting cholangiocarcinoma.<br/>ΔΔ Approximately 95% of LR-M lesions are malignant. Slightly less than one-half of malignant cases are HCC and the remainder are non-HCC malignancies (eg, cholangiocarcinoma, combined HCC-cholangiocarcinomas, lymphoma, or metastases).<br/><font class="double_lozenge">◊◊</font> Biopsy may alter management for patients being evaluated for liver transplant or for other nonsurgical locoregional therapies (eg, thermal ablation), or if serum tumor markers suggest intrahepatic cholangiocarcinoma or metastasis from an extrahepatic malignancy.</div><div class="graphic_reference">Reference: 

<ol>
<li>American College of Radiology. Liver Reporting &amp; Data System v2018. <a href="https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS" target="_blank">https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS</a> (Accessed on August 21, 2018).</li></ol></div><div id="graphicVersion">Graphic 116155 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
